OSE Immunotherapeutics - Positive Tedopi step 1, rethinking its future
On 1 April 2020, OSE announced that the primary endpoint was met in the predefined step 1 analysis of the Phase III Atalante 1 trial with OSE’s...
632 Views
OSE Immunotherapeutics - Progress with key R&D assets
OSE has a well-balanced R&D pipeline in terms of asset stage and technology. In the near term, much of the focus is on Tedopi, an off-the-shelf...
762 Views
OSE Immunotherapeutics - R&D progress triggers milestone payment windfall
OSE Immunotherapeutics now has four clinical trials running. Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a...
881 Views